Send us Feedback

Cephalon (CEPH)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

CEPH » Topics » Development Costs.

This excerpt taken from the CEPH 10-Q filed Aug 9, 2005.
Development Costs.  All Initial Indication Development Costs shall be paid by Alkermes.  All other Development Costs for activities conducted under a Development Plan hereunder shall be Shared Expenses and shall be subject to offset or credit against amounts due pursuant to Section 9.5 below

 

"Development Costs." elsewhere:

Amylin Pharmaceuticals (AMLN)
Medivation (MDVN)
Gilead Sciences (GILD)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki